Market Size of Imatinib Drug Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 3.00 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Imatinib Drug Market Analysis
The Imatinib Drug Market is expected to register a CAGR of 3% during the forecast period. Several factors are propelling the growth of this market such as increasing prevalence of cancer, increase in demand of target drug therapy and patient expiry of imatinib drug. For instance, according to National Cancer Institute in 2017 the number of new cases for leukemia is 62,130 and number of deaths was 24,500 which shows increasing prevalence of cancer patients in future and propell the imatinib drug market. In addition, Food and Drug Administration (FDA) approves enasidenib (IDHIFA®) a target drug therapy for patients who has Acute myeloid leukemia (specifically genetic mutation IDH2). Moreover, Imatinib drug is helpful in treating the patient with cancer by blocking the growth of eosinophils. This drug has been attributed to its higher efficacy in treating the Chronic Eosinophilic Leukemia, Hyper-Eosinophilic Syndrome, Gastrointestinal Stromal Tumors (GIST) and many more, However, high cost of imatinib with several substitute such as tarceva, sprycel and tasigna may hamper the market to certain extent.